Results 101 to 110 of about 17,271 (194)

Abiraterone [PDF]

open access: yesReactions Weekly, 2020
openaire   +2 more sources

Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health Professionals

open access: yesCancer Control
Introduction The burden of prostate cancer (PCa) is disproportionately concentrated in low- and middle-income countries (LMICs). Abiraterone and enzalutamide have improved survival rates and quality of life for men with PCa.
Omolara Fatiregun MBBS, FWACS, MSc   +17 more
doaj   +1 more source

A multicenter analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer

open access: yes, 2014
Introducton: The COU-AA-301 trial showed that abiraterone acetate (abiraterone), an oral cytochrome p450 CYP17 inhibitor, improved survival for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel.
Emmenegger, Urban   +10 more
core   +1 more source

Efficacy of Abiraterone in castration resistant prostate cancer

open access: yes, 2020
Introducción y objetivo: La Abiraterona es uno de los medicamentos aprobados desde el 2009 para el manejo del cáncer de próstata resistente a la castración (CPRC).
Quiroga Matamoros, William   +2 more
core  

Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.

open access: yes, 2016
329 Background: Abiraterone acetate is rapidly hydrolyzed to the active abiraterone in vivo. In order to study the relation between drug exposure and therapeutic effect an assay to determine plasma concentrations of abiraterone is required.
Mette Benoist   +6 more
core   +1 more source

Investigating the Anti-Tubercular Potential of Novel Non-Antibiotic Agents against Drug-Resistant Mycobacterium Tuberculosis

open access: yesBioscientific Review
Background. The ever-increasing prevalence of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) presents an alarming challenge to existing tuberculosis (TB) treatment stratgies.
Muhammad Fayaz Khan   +6 more
doaj   +1 more source

A novel RP-HPLC stability-indicating method for simultaneous estimation of Niraparib and Abiraterone in synthetic mixtures and combined tablet formulations

open access: yesDiscover Applied Sciences
Niraparib and Abiraterone in a combined dosage form offer a fortunate regimen for treating cancers, mainly those resistant to conventional therapies cast in cancer treatment.
Krishnaphanisri Ponnekanti   +4 more
doaj   +1 more source

Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).

open access: yes, 2014
240 Background: Abiraterone is a 17a hydroxylase and C17,20-lyase inhibitor that blocks androgen biosynthesis and is approved for treatment in patients with mCRPC.
Rahul Atul Parikh   +3 more
core   +1 more source

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer

open access: yesAdvanced Science
Castration‐resistant prostate cancer (CRPC) remains the leading cause of mortality among prostate cancer patients. While second‐generation androgen receptor (AR) pathway‐targeted therapies, such as Abiraterone, have significantly improved survival ...
Liling Jiang   +18 more
doaj   +1 more source

Home - About - Disclaimer - Privacy